Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the data from this study will be fully interpreted or will be submitted to medical meetings in the future. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Rebecca Gregory, Corporate Communications of ImClone SystemsIncorporated, +1-646-638-5058, ; or Media, Madeline Malia,+1-609-252-3347, , or Tony Plohoros, +1-609-252-7938,, or Investors, John Elicker, +1-212-546-3775,, all of Bristol-Myers Squibb media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicker@bms.com

Web site: http://www.bms.com/http://www.ERBITUX.com/

Ticker Symbol: (NYSE:BMY),(NASDAQ-NMS:IMCL)

Terms and conditions of use apply
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 1Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 1SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 4Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 1Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 2Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 3 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 1 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 2
...NGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap...maceutical company focused on,the discovery and de...ay announced encouraging preclinical data of AV-41...nhibitor of EGFR/HER2 using,AVEO,s unique EGFR mut...he results from the preclinical study showed that ...
...r Presentation on April 17, 2007 at AACR, SAN DIEG...aceuticals, Inc. presented data from an in vitro s...promotes natural killer (NK),cell-mediated anti-tu...ysis of tumor cells and enhanced antibody-dependen...esentation at the Annual,Meeting of the American A...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
(Date:12/2/2008)...irstCall/ -- Neuralstem Inc.,(NYSE Alternext US: ...ollaboration with the China Medical University &am...Neuralstem,s human spinal cord neural stem cell,t...phic Lateral Sclerosis (ALS,or Lou Gehrig,s disea...,investigator. , (Logo: http://www.newscom...
(Date:12/2/2008)...ia-FirstCall/ -- China Sky One Medical,Inc. ("Ch...CSKI ), a leading,fully integrated pharmaceutical...People,s Republic of China ("PRC"), announced toda...f Financial Officer and Secretary and will,also s...aces Yu-kun Zhang, who,had served as interim CFO ...
(Date:12/2/2008)...Call/ -- Mylan Inc. (NYSE: MYL ) today,announce...s Inc., have entered,into a settlement agreement ...p. and Novartis International AG related to Letroz...ara(R). , Mylan,s Vice Chairman and CEO Rob...ave reached this agreement, which demonstrates our...
(Date:12/2/2008)...ire/ -- In response to the commentary entitled "Co...ory Infections, and the Vitamin D Deficiency Epide...upplement experts, Nordic Naturals announced today... compromise to consumers and actually offer health...al Vitamin A. According to Karin Yien, MD, Nordic ...
Breaking Medicine News(10 mins):Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2
...uta of the Salvation Healing Ministry, who is a se...rt on charges of swindling six people of Sh1.6 mil...le that they would be cured of HIV/AIDS through pr...te, Margaret Muigai, denied her bail since Central...
...acco by youngsters will cost their dear lives and ...people a year, which will greatly affect the count...me to over 250 million tobacco users and more than...ated diseases every year. But the most ominous sig...
...l carried out to treat diabetic nerve damage has s...vered by researchers// of the University of Manche...to trigger a particular gene responsible to preven...tic neuropathy. The positive preclinical results...
...spitals revealed falling standards of cleanliness .... Comparing to 56 percent people in 2002, only 52...y about 51 percent in 2003 said lavatories were ve.... Contradicting the above, the annual NHS patients...
Other Medicine News:Health News:Tobacco Consumption By Youths Will Hamper India’s Economic Growt 2Health News:New Gene Therapy Treats Diabetic Neuropathy 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: